Journal
UPSALA JOURNAL OF MEDICAL SCIENCES
Volume 124, Issue 1, Pages 65-69Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/03009734.2018.1490831
Keywords
Heart failure; registry; RiksSvikt; SwedeHF
Categories
Funding
- Swedish Research Council [2013-23897-104604-23, 5232014-2336]
- Swedish Heart and Lung Foundation [20120321, 20150557]
- Relypsa Inc.
Ask authors/readers for more resources
Heart failure (HF) represents a global pandemic. Although in HF with reduced ejection fraction (HFrEF) randomized controlled trials have provided effective treatments, prognosis still remains poor, with signals of undertreatment. HF with mid-range EF (HFmrEF) has no evidence-based therapy, and its characterization is ongoing. Trials in HF with preserved EF (HFpEF) have failed to provide any effective treatment, but there are several concerns about their design. Thus, current challenges in the HF field are: 1) optimizing the use of existing treatments in HFrEF; 2) developing and proving efficacy of new treatments, and of new use of existing treatments in HFpEF and HFmrEF. Here we describe how registry-based research can improve knowledge addressing the unmet needs in HF, and in particular we focus on the contribution of the Swedish Heart Failure Registry to this field.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available